• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌间歇性激素疗法的实验性治疗

Experimental treatment of prostatic cancer by intermittent hormonal therapy.

作者信息

Trachtenberg J

出版信息

J Urol. 1987 Apr;137(4):785-8. doi: 10.1016/s0022-5347(17)44211-x.

DOI:10.1016/s0022-5347(17)44211-x
PMID:3560348
Abstract

In order to determine if intermittent hormonal therapy might prove to be beneficial in the treatment of prostatic cancer, animals bearing the Dunning R3327H prostatic adenocarcinoma were castrated and intermittently subjected to hormonal stimulation by means of indwelling silastic testosterone-filled implants. The growth of these tumors, as measured by increases in volume, was compared to that of a castrate control group, a chronic implant group and an intact control group. By the end of an initial 49 day experimental period there was no significant growth reduction with the intermittent stimulation group as compared to the implanted control or intact groups. The castrate group had a significant lower rate of growth than any other group. The incidence of massive tumor growth or tumor necrosis was significantly lower in the castrate group than the other groups by the end of the 16 week experimental period. Intermittent hormonal therapy is clearly inferior to early castration in preventing tumor growth; furthermore it does not appear to offer any growth-retarding advantages when compared to delayed hormone therapy. The most effective growth-retarding technique for the Dunning R3327H hormone dependent prostatic adenocarcinoma is early castration.

摘要

为了确定间歇性激素疗法是否可能被证明对前列腺癌的治疗有益,对携带邓宁R3327H前列腺腺癌的动物进行去势,并通过留置填充有睾酮的硅橡胶植入物间歇性地给予激素刺激。将这些肿瘤的生长情况(通过体积增加来衡量)与去势对照组、慢性植入组和完整对照组进行比较。在最初的49天实验期结束时,与植入对照组或完整组相比,间歇性刺激组的肿瘤生长没有显著降低。去势组的生长速度明显低于其他任何组。在16周实验期结束时,去势组中大量肿瘤生长或肿瘤坏死的发生率明显低于其他组。间歇性激素疗法在预防肿瘤生长方面明显不如早期去势;此外,与延迟激素疗法相比,它似乎没有提供任何延缓生长的优势。对于邓宁R3327H激素依赖性前列腺腺癌,最有效的延缓生长技术是早期去势。

相似文献

1
Experimental treatment of prostatic cancer by intermittent hormonal therapy.前列腺癌间歇性激素疗法的实验性治疗
J Urol. 1987 Apr;137(4):785-8. doi: 10.1016/s0022-5347(17)44211-x.
2
Optimal testosterone concentration for the treatment of prostatic cancer.
J Urol. 1985 May;133(5):888-90. doi: 10.1016/s0022-5347(17)49273-1.
3
Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats.前列腺癌的激素和化学治疗;哥本哈根-费舍尔大鼠的前列腺邓宁腺癌
Oncology. 1985;42(1):48-54. doi: 10.1159/000225999.
4
Role of prolactin in modulating the effects of tamoxifen on growth of the Dunning R3327 rat prostate adenocarcinoma.催乳素在调节他莫昔芬对邓宁R3327大鼠前列腺腺癌生长的影响中的作用。
Prostate. 1987;10(1):57-67. doi: 10.1002/pros.2990100109.
5
Effect of medroxyprogesterone acetate, alone or in combination with epirubicin hydrochloride, on the growth of the Dunning R3327H prostatic adenocarcinoma.
Eur Urol. 1987;13(3):203-6. doi: 10.1159/000472774.
6
Antiestrogens do not counteract the inhibitory effect of estradiol-17 beta on the growth of the Dunning R3327 prostatic adenocarcinoma.抗雌激素不能抵消雌二醇-17β对邓宁R3327前列腺腺癌生长的抑制作用。
Prostate. 1988;12(4):287-98. doi: 10.1002/pros.2990120402.
7
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).用雄激素去除与Trk酪氨酸激酶抑制剂CEP-751(KT-6587)或CEP-701(KT-5555)联合治疗的Dunning H大鼠前列腺癌在体内持续消退。
Cancer Res. 1999 May 15;59(10):2395-401.
8
Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology.用醋酸甲羟孕酮(MPA)治疗大鼠前列腺腺癌:对生长和形态的影响。
J Urol. 1991 Jun;145(6):1283-7. doi: 10.1016/s0022-5347(17)38615-9.
9
Coordinate loss of growth regulatory factors following castration of rats carrying the Dunning R3327 G prostatic tumor.携带邓宁R3327 G前列腺肿瘤的大鼠去势后生长调节因子的协同丧失
Clin Physiol Biochem. 1992;9(2):47-50.
10
Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
Cancer Res. 1991 Apr 1;51(7):1760-5.

引用本文的文献

1
Intermittent versus continuous androgen deprivation in prostate cancer.前列腺癌的间歇性与连续性雄激素剥夺治疗。
N Engl J Med. 2013 Apr 4;368(14):1314-25. doi: 10.1056/NEJMoa1212299.
2
Intermittent androgen suppression for prostate cancer.间歇性雄激素抑制治疗前列腺癌。
Nat Rev Urol. 2010 Oct;7(10):552-60. doi: 10.1038/nrurol.2010.141. Epub 2010 Sep 14.
3
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective.生化(前列腺特异性抗原)复发:肿瘤学家的观点。
Rev Urol. 2003;5 Suppl 2(Suppl 2):S3-S13.
4
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective.生化(前列腺特异性抗原)复发:肿瘤学家的观点。
Rev Urol. 2003;5 Suppl 3(Suppl 3):S3-S13.
5
Intermittent androgen deprivation.间歇性雄激素剥夺
Curr Oncol Rep. 2000 Sep;2(5):409-16. doi: 10.1007/s11912-000-0060-6.